Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults (BOOST-X)
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Craig Tuggle, MA
- Numero di telefono: 850-202-4416
- Email: ctuggle@ihmc.org
Luoghi di studio
-
-
Florida
-
Pensacola, Florida, Stati Uniti, 32502
- Florida Institute for Human and Machine Cognition
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Male or female aged 60 years or older
- Free of chronic disease or disorder that would preclude full participation or have the potential to confound results
- No structured exercise program (2 or more bouts/wk) within previous 12 months
- Cognitively capable of providing informed consent
Exclusion Criteria:
- BMI ≥ 30.0 kg/m2
- Neurodegenerative disease
- Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and/or physical performance testing
- Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.
- Resting blood pressure <90/60 mmHg or >160/95 mmHg
- Uncontrolled hypertension
- Any current cardiovascular disease or cardiopulmonary instability
Recent cardiovascular event or procedure within the preceding 6 months
- If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure
- Any mechanical valve replacement that requires continuous warfarin anti-coagulation
- Anemia: Hgb <11.0 (♂),10.0 (♂) gm/dl
- Diabetes with HgbA1c >7.0% or fasting blood glucose ≥ 130 mg/dl
- Liver disease with ALT > 52 U/l)
- Chronic kidney disease (eGFR < 45)
- Any current infectious disease
- Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)
- Life expectancy < 1 year Medications / lifestyle
- Insulin sensitizing/blood glucose lowering agents such as metformin
- Currently on or have used GLP-1 agonist or other metabolic / weight loss drug in previous 12 weeks
- Use of nitrate medications
- High dose statin (≥40 mg/d simvastatin equivalence)
- Chronic corticosteroids
- Testosterone or other anabolic/androgenic hormone therapy
- Lidocaine allergy
- Regular tobacco use and/or vaping > 1/wk
- Use of cannabis > 1/wk
- Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/d or 14 drinks/wk for males)
- Use of illicit drugs (e.g., cocaine, opioids)
- Unable to commit to ~4 months required to complete the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Nitrate Group
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
|
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions.
During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets.
On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions.
RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.
|
|
Comparatore placebo: Placebo Group
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-deprived, manufacturer-matched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
|
All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions.
During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets.
On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions.
RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.
Manufacturer-matched placebo that is nitrate-depleted beetroot juice (70 ml per drink).
Both nitrate and placebo will be purchased from Beet It.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Assess the clinical impact of nitrate supplementation on a proportion of older adults attaining exercise-induced health benefits.
Lasso di tempo: 12 weeks
|
The primary outcome will be assessed using logistic regression with the proportion not attaining Cardiorespiratory Fitness and functional Muscle Quality Minimally Clinical Differences as the response variable and treatment adjusted for sex and age group across the 12 week intervention.
|
12 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cardiorespiratory demand during submaximal cycle exercise.
Lasso di tempo: 12 weeks
|
Supportive analyses will include secondary (cardiorespiratory demand during submaximal steady state exercise) outcomes.
The steady state exercise cycling will be 10 minutes at 60% of peak power (Watts) during the VO2 peak test.
|
12 weeks
|
|
Neuromuscular fatiguability during isometric holds.
Lasso di tempo: 12 weeks
|
The knee extensors will perform a 30 second isometric flexion on a dynamometer.
The fatigue will be defined by the force decline across the 30 seconds.
|
12 weeks
|
|
10 meter max gait speed.
Lasso di tempo: 12 weeks
|
Participants will walk as quickly as possible across a 10 meter, straight course.
Time is recorded for up to three attempts.
A lower time indicates a faster speed.
|
12 weeks
|
|
modified Balance Error Scoring System (mBESS)
Lasso di tempo: 12 weeks
|
Stability is assessed with the Sway Medical tablet app via three stances: double-leg, single-leg, and tandem.
Scoring is decided by losing balance or opening eyes during closed eyed tests.
|
12 weeks
|
|
NIH PROMIS Physical Function SF
Lasso di tempo: 12 weeks
|
The NIH PROMIS Physical Function Short Form (SF) is a standardized tool used to evaluate an individual's physical abilities and limitations in daily activities.
It is part of the broader Patient-Reported Outcomes Measurement Information System (PROMIS), which focuses on measuring patient-reported outcomes across various health domains.
|
12 weeks
|
|
NIH PROMIS Fatigue SF
Lasso di tempo: 12 weeks
|
PROMIS Fatigue SF refers to the short form of the Patient-Reported Outcomes Measurement Information System designed to assess fatigue levels in patients.
It provides a standardized way to measure fatigue, which can be used in various clinical settings to evaluate patient health status.
|
12 weeks
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cognitive function.
Lasso di tempo: 12 weeks
|
Cognitive function is assessed via Sway Medical reaction time via three assessments: visual processing speed: measures how quickly a person can interpret visual information.
|
12 weeks
|
|
Psychological state.
Lasso di tempo: 12 weeks
|
Depression and anxiety are assessed via the well-validated Patient Health Questionnaire 9 (PHQ-9) both via Sway.
The PHQ-9, or Patient Health Questionnaire-9, is a tool used to screen for, diagnose, and measure the severity of depression.
It consists of nine questions that assess how often a person has experienced symptoms of depression over the past two weeks.
|
12 weeks
|
|
Sleep quality and nocturnal stress.
Lasso di tempo: 12 weeks
|
Perceptions of sleep quality are measured using the short forms (SF) of PROMIS Sleep Disturbance and Sleep-Related Impairment.
For direct monitoring, participants wear an Oura Gen-4 ring to quantify sleep behavior with stress monitored via Heart Rate /Heart Rate variability (HRV) across the full enrollment period, as we have done in previous studies including the ongoing NIA M3AX Trial (NCT06507189).
The Oura ring is well validated against polysomnography for several sleep metrics and nocturnal HR/HRV.
|
12 weeks
|
|
Free-living activity via the Oura Gen 4.
Lasso di tempo: 12 weeks
|
Free-living activity is also monitored daily via the Oura Gen-4 ring worn throughout trial participation.
Variables such as step count and heart rate will used to determine activity.
|
12 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- IRB-2026-0019
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .